PARENTERAL BIOTECH LIMITED I · 2016-04-25 · PARENTERAL BIOTECH LIMITED Regd. Office.: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andlieri (West), Mumbai- 400 053

PARENTERAL BIOTECH LIMITED Regd. Office.: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andlieri (West),

Mumbai- 400 053

I BOARDS' REPORT -

To Thc Members of Pi~rcntcral Biotccl~ Li~iiited

The Directors of your Company are pleased to present tlie 19'" Annual Repost together witli the audited financial statement of tlie co~i ipany for the financial year ended 3 1 " Mxcl i , 201 5.

1 FINANCIAI, RESULTS AND T H E S'I'ATF, OF COMPANYS' AFFAIRS

Dur ing the y e a r undcr r ev iew tlic C o m p a n y did not ca r ry o u t any opera t ing activit ies.

I DIVIDEND I

Tlle Board of Directors espress their inability to recornmend any Dividend for the Financial year u~ider review.

Shri Vinod ICumar Cupta (DIN:00039145), Director of tlie company is liable to retire b j rotation at tlie fortllco~ning Annual General Meeting and being eligible, offers liirnself for re-appoint~iient.

CONTRACTS AND ARRANGEMENTS WITH RELATED PARTIES

As tlie company lias not com~lienced its busi~less operations. tliere were no contracts witli the rclated pal-ties during the ycar under review.

Your Directors draw attention o f tlie membcrs to Note 16 to tlie financial statement which sets out related party disclosures as per AS- 18.

MIS. ' f . N . U~ln i CQ Co.. Chartesed Accountarits, Statutory Auditors of the Co~npan! bearing Firm I<cgistratioli No. 004890C, retiring at tlie ensuing Annual General M e e t ~ n g of tlie Company ancl proposed to be re-appointed as the statutory auditor o f the Company from tlie c o ~ i c l ~ ~ s i o ~ i o f the ensuing Annual General Meeting t i l l the conclusion o f the nest Annual General hlleeting of the Cornpan).

As recluired under section 139 of the Companies Act, 2013, the Company lias obtained a \\ rittcn consc~it fsom MIS. T.N. Unni & Co., Chartered Accoun ta~~ts , to s i ~ c h re-appointmelit and also a cc~t i f ica te to tlie effect that their re-appointment, if rnadc, would be in accordance \\it11 tlic psovisions o f section 139(1) and section 141 of tlie C o ~ n p a l i ~ e s Act, 2013 and rules made thcreundcr, as ma) be applicable.

Corporate Office- Shree Ganesli Chambers, Navlakha Square, A.B. Road, Indore (M.P)-45200 I CIN- U24130MM 1995PLC094930

PARENTERAL BIOTECH LIMITED Regd. Office.: 340, Laxlni Plaza, Lax~ni Industrial Estate, New Link Road. Andlieri (West).

Mumbai- 400 053

Tlie report of thc Statutory Auditors does not contain ally qualification, ~reser\/ation or ad\~ersc remark or- disc1ainie1- and thc same is self explanatory and do not call for ally f~~rt l ier comnlcnts fro111 tlie Board.

1 RISK MANAGEMENT

As the colnpany has not coniriienced its business operations, there is no recluirement of Risk Managenlent i n tlie company during tlie year under revieiv.

I FIXEI) DEPOSIT

Tlie coliipany lias not accepted deposits during the year under review neither covered under Chapter V of tlie Conlpanies Act, 2013 nor otherwise. No amount lias remained unpaid or i~nclaimed as at the end of the year, therefore, there is no default in repayment of deposits or paymcnt of interest thereon during tlie year under review.

1 PARTICULARS OF EMPLOYEES 1 --

Durilig thc year under review. none o f the employees o f the Cotnpany was in receipt of remuneration Ibr the year which. in the aggregate. was not less than sixty lakli rupees.

1 CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION & FOREIGN EXCHANGE EARNINGS & OUTGO

Particulars pel-taining to tlie Conservatio~~ of Energy, Technology Absorptiori and Foreign Exchange Earnings 8r Outgo as prescribed under scction 134 of the Companies Act, 20 13 read with tlie Companies (Accounts) Rules, 20 14, are not applicable to tlie company.

/ DIRECTORS' IIESPONSIBILITY STATEMENT

Pursuant to tlie provisions of section 134 of tlie Companies Act. 20 13, with respect to the Dil.ecto~,s' Iiesponsibility Statelllent. it is hereby confinned that:

( i ) it1 the preparation of annual accoun~s for tlie year ended 3 1 " March. 201 5, tlic applicable Accounting Standards have been followed along with proper explanation relating to material departures;

(ii) the Directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent. so as to give a true and fair view of the state of affairs of tlie Co~npanr as at tlie end of the financial year elided 011 3 1 " March. 20 15 and of the profit and loss of tlie Co~npa~ ly for tlie financial year ended 3 I " Marcli, 20 15;

(iii) the Directors have taken proper and sufficient care for tlie maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 3013, for safeguarding tlie assets o r the Company and for preventing and detecting fraud and other irregularities:

COI-porate Office- Shree Garlesh Chambers. Navlakha Square, A.B. Road, lndorc (M.P)-45300 1 CIN- U24230MH 1995Pl,C094930

PARENTERAL BIOTECH LIMITED Regd. Office.: 340. Laxmi Plaza, Laxmi Industrial Estate, New Lirik Road, Andheri (West).

, , Mumbai- 400 053

( the Directors l i a ~ e prepared tlie annual accounts for the financial year ended 3 1 " March, 201 5 on a going concern basis;

(\I) the Directors has laid down internal financial controls to be followed by the company and tliat sucli internal controls are adequate and were operating effectively;

(vi) the Directors llad devised proper systems to ensure co~npliance with the provisions of all applicable laws and tliat sucli systems were adequate and operating effectively

DISCLOSURES

i. There is 110 change i l l the nature of business of tlie colnpany during the year under re\/ ie\v.

i i . During the ycar under review, tlie company was not required to constitute the Noniination and Remuneration Co~nmittee.

iii. Thc Board has establishecl Vigil Mcclianisrn for directors arid e~nployees of the company.

iv. [Illring the year under review, tliere are no material changes and con~mitments affecting the l'inancial position of the company wliich have occurred between tlic end of the financial year to \vliich the financial statements relate and tlie date of report.

v. There has beer1 no significant and ~naterial orders passed by tlie regulators or courts or tribunals impacting the going concern status and conipany's operations in fi~ture.

vi. Tlie internal financial controls with reference to the financial statement of the company are adequate and commensurate to tlie size of the company.

vii. l'lie extract of An~iunl Return of tlic colilpaliy is annexed herewit11 as Annesure-I to this report.

viii.Tlie [ha rd of Directors met six (6) times during tlic financial year 2014-201 5 . Tlie niaxi~num time gap between two (2) consecutive meetings did not esceed one hundred and twenty clays.

is. During tlie year under review, tlie Co~npa~iy has neither given any guarantee or provided ally sccurity ill connection with a loan to any other body corporate or person nor invested any f'i~nd i l l tlie securities of any other body corporate or extended loan to all) company. tIowe\/er. the company llas given loan to a related party.

s. During the year under review, tlie company had no profits and therefore the company cloes not propose to carry any amount to its reserves.

xi. Tlie provisions of section 135 of tlie Companies Act, 2013 read wit11 Companies (Corporate Social Responsibility Policy) Rulcs, 2014 related to Corporate Social Responsibility is not applicable as tlie company does not meet tlie criteria specified therein.

xii. Tlle Conipany has neither the Managing Director nor tlie Whole-Tinie Directors on the Board of the company who are in receipt of any comniission from tlie company. I-lowever, Mr. Manohar 1,al Gi~pta (DIN: 00030784), Mr. Vinod I<umar Ciupta (00039 145) and Mr. Govind Das Ciarg (00520067). Non-esecutive Directors of (lie company receives remuneratio~l from Parenteral Drugs (India) Limited, Holding company.

xiii.During tlie year under rcvicw, tlie company Lvas not required to appoint any Independent Director so there was no require~ncnt of disclosure under the provisions of section 149 of tlle Co~iipanies Act, 20 13.

Corporate Office- Shree Ganesll Cliambcrs, Navlaklla Square, A.B. Road, Indore (M.P)-45200 I CIN- U24230MH 1995PLC094930

PARENTERAL BIOTECH LIMITED Regd. Office.: 340. Laxmi Plaza, L a s ~ n i Industrial Estate, New Link Road, Andliel-i (West),

Mi~mbai- 400 053

s i \ ~ . A s rcported by the statutoty auditor of tlie company, tliere are no such frauds other than those which are reportable to Central Government under section 143(12) of the Colnpanies Act, 20 13.

s v . The company is not required to give any disclosure under the provisions of sub-section (3) of section 67 of the Companies Act, 201 3.

xvi.No cases of sexual harassment \\/ere reported i n the last financial year. svii. The company Iias neither any subsidiary company nor J V or Associate companies

and hence neither any company has become or ceased to be subsidiary, Joint Venture or Associate company of tlie coliipany during the year under revie\\ slid thus, no reporting is required on their performance. f-lowever, tlie company is a wl~olly owned subsidiary of I'arenteral D ~ L I ~ S (India) Limited, Holding company.

1 A C K N O W L E D G E M E N T S

The Directors would like to cspress their appreciation for tlic assistance and co-operation rcccived fi.orii Bankers. Government autho~.ities, c l~ston~ers , and vendors duririg tlie year. Your Directors also \visli to place on record their deep sense of appreciation for the committed services of Esecutivcs, Staff and workers of tlic Company.

FOR AND ON B E H A L F OF THE BOARD

I'lace: I~ l t lo re Datc: 03.08.2015

Vinod K u m a r Gupta Govincl Das G a r g Director Director

(DIN: 00039145) (DIN: 00520067)

Corporfl'e Ol'fice- Sliree Gnnesh Clianihel.~. Navlaklia Square, A.B. Koad. Indore (M.P)-45200 I CIN- U2423OMH 1995l'l,C094930

FORM NO. MGT-9 EXTRACT OF ANNUAL RETURN

As on financial year ended on 31.03.2015

[Pursuant to Section 92 (3) of the Companies Act, 2013 and rule 1211) of the Company (Management & Administration) Rules, 20141

I . REGISTRATION & OTHER DETAILS:

I - I . . . 1 I I I Name ol'the Conipony / Parentcral Biotech Limited ! I iv. I CategoryISub-category o f / Company Limited by shnres/lndian Non-Government Company i

Address o f the Registered office & contact details

340, Lasmi Plaza, Laxmi Industrial Estate, New Link Koad, Andlieri (W). Mumbai, Maliarashtra- 400 053 Ph. NO. 022-6 1725900-1 Fax No. 022-26333763

11. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY (All t h e bus iness activities contr ibut ing 10 O/o o r m o r e of t h e total t u r n o v e r of t h e company shall be s t a t ed )

vi.

i

1 S. No. 1 Name a n d Description of main / NIC Code of t h e ( % t o total t u r n o v e r of t h e 1

Whether listed company

Name, Address & colltact details o f the Registrar & Transfer Agent. if any .

1 1 prodocls 1 activit ies d u r i n g t h e year .

Emnil Ict : [email protected]~n

No

Not Applicable

1

111. PAR7'ICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES -

produc t s / services

Man~lfacturing of Pharmaceutical

Product /service

6870

APPLICABLE SECTION

_ _-- L j.-. - t 1 Parenteral Drugs (India) L99999MH1983PLC126481 / Holding 5 1 , 2(87) (i) & (ii)

l imited I

c o m p a n y

T h e Company has n o t rading

941 OF SHARES

HELD

340, Laxmi Plaza, 1 taxrni Industr ial Estate. ~ New Link Road, Andheri (W) , IMumbai- 400 053

HOLDING/

SUBSIDIARY

/

I I

CIN/GLN S. NO.

I I

NAME AND ADDRESS OF

THE COMPANY

c) Central Govt

0 0

d j ~ t a t e I 0 0

0 Govt(s) e) Venture Capital Funds

0

0

nsilrance 0 0 0 0 0 0

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

o

0

Capital Funds I i) Others (specify) Sub-total

0

0

0

0

0 1

0

2. Non- Institutions

1 a) Bodies 1 Corp.

i) Indian

0

0

0

0 1

o ! 0

0 /

0

0

0

0

0

0

0

0 1 ii) Overseas 0 / 0 1 0 / 0 / b) Individuals i ) Individual 0 shareholders holding nominal share capital

1 lipto Rs. 1

shareholders holding nominal

I share capital 1 in excess of

I Rs. 1 lakh

0

0

0

0 /

I

0 / 0

0

0

0

0

0

0

0

0

0

0 /

0

0

0 1

0

0

0

0

0

0

0

0 1

0

0

0

I

O I

c) Others (specify) (i) Non Resident

0 / 0

0

I

I

0

0

1

0

0

0

0

ii,,); I Resident 1 Indians (Non

Repat)

(iii) Clearing Member

(iv) Directors / Relatives

(v) 'Trusts

0

0

0

- - - -

0 1 1

o - - - - -

0

0

0

0 1

0

0 ,

0 '

- - - -

Sub- total 1 o / (B) (2) :-

- --- -----

0 1

0

- - - - -

0 1 0 1

0

I

0

0

0

0

- - - -

0

0

0

- -----

0 '

0 .

0 '

0

0

0

0

0

0

0

0

0

- - - - -

0

- - -

iv) Shareholding Pattern of top ten Shareholders (Other than Directors, Promoters and Holders of GDRs and ADRs):

I-

Top 10 shares total 1 1 I 1 shares 1 shares ol

Date wise Increase,/ Decrease

in Promoters Share holding

during the year specifying the

reasons for increase / decrease

(e.g. allotment / transfer / bonus/ sweat equity etc):

A t the end o f the year

For Each of the

Shareholders , / shares of / 1 I 1 the I

There is no change in Promoters' Shareholding between 01.04.2014 to

31.03.2015

I

the company

Shareholding a t the beginning of the year

No. of 1 O/O of

Not Applicable, as the company is having no shareholder in this category. --e V) Shareholding of Directors and Key Managerial Personnel:

Date

No.

Increase/ Decrease in Shareholding

1 SI. Directors and KM P

For each of the 1 Shareholding a t the I Date I Increase/ 1 Reason / At the end of the beginning of the year

Reason Cumulative Shareholding

during the year

No. of I O/O of tota

Decrease in Shareholding

No. Of shares shares total

shares of

O/O of total shares of the company

1 2 ) *Mr. Virlod Kumar I lo 1 0.004 ~ - I - I - 1 10 0.004

1. *Mr. Manohar Lal

*Held by nominee shareholders o n behalf o f Parenteral Drugs (India) Limited, Holding Company.

3.

4 *Mr. Aditya Gupta

10

10 *Mr. Govind Das Gasg

10

0.004

0.004

0.004

-

-

-

10

1 0

company 0.004.

0.004

10 0.004. -

8. Remuneration to other directors:

iKpGGzSN.-- Remuneration

Name of Directors

- It was not required to appoint Independent Director on the Board of the Company pursuant to the provisions of the Companies Act, 2013. Also,

1 co~nnii t tee meetings 1 Tlie company has neither paid any fees for attending board or 1 committee meetings nor any commission to the Nan-Executive Directors

hers, please specify / of the Cornpany during the financial year 01.04.2014 to 31.03.2015,

1 I Total (1) 1 1 2 1 Other Non-Executive I

Fee for attending board committee meetings Commission Others, please specify

Total (2)

I Total (B)=(1+2) Total Managerial

I I Remuneration I Overall Ceiling as per the Not Applicable

C. REMUNERATION TO KEY MANAGERIAL PERSONNEL OTHER THAN MD/MANAGER/WTD:

SN Particulars of I Rcmancration Key Managerial Personnel

I

1

I -I / Com~nission I 1 -as % of profit

1

I

Gross salary

(a) Salary as pcr provisions contained ill

sectio~i 17(1) of the Income-tax Act, I96 1 (b) Value of perqi~isitcs 111s 17(2) Income-tax Act, 1961 (c) Profits in lieu of salary

2 Stuck Option

5

I

1 under section 1 7 ( 3 ) Inco~iic-tnh Act. 196 1

CEO

I I I I

I .l'otal

-otl~e~-s. specify.. . Others, please specif)

CS

I

CFO Total

T.N. UNNl & Co. CHARTERED ACCOUNTANTS

402, Alankar Point 4-A, Rajgarh Kothi

Geetha Bhawan Square, A.B. Road, INDORE - 452 001

INDEPENDENT AUDITORS' REPORT

TO THE MEMBERS OF PARENTEM BIOTECH LIMITED

REPORT ON THE FINANCIAL STATEMENTS

We have audited the accompanying financial statements of Parenteral Biotech Limited ("the Company"), which comprise the Balance Sheet as at March 31, 2015, the Profit and Loss Statement, the Cash Flow Statement for the year then ended and a summary of significant accounting policies and other explanatory information.

MANAGEMENTS RESPONSIBILITY FOR THE FINANCIAL STATEMENTS

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 (''the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

AUDITORS' RESPONSIBILITY

Our responsibility is to express an opinion on these financial statements based on our audit. We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made there under.

We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatements.

T.N. UNNl & Co. CHARTEREDACCOUNTANTS



An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on whether the Company has in place an adequate internal financial controls system over financial reporting and the operating effectiveness of such controls. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by the Company's directors, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

OPINION

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 201 5, and its loss and its cash flows for the year ended on that date.

REPORT ON OTHER LEGAL AND REGULATORY REQUIREMENTS

1. As required by the Companies (Auditor's Report) Order, 201 5 ("the Order") issued by the Government of India in terms of the Sub Section (1 1) of Section 143 of the Act we give the Annexure a statement on the matters specified in paras 3 and 4 of the Order, to the extent and as applicable.

2. As required by Section 143(3) of the Act, we report that;

a) We have sought and obtained all the information and explanations which to the best of or knowledge and belief were necessary for the purposes of our audit;

b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;

c) The Balance Sheet, the Profit and Loss Statement, and the Cash Flow Statement dealt with by this Report are in agreement with the books of account:

T.N. UNNl & Co. CHARTEREDACCOUNTANTS



d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014;

e) On the basis of the written representations received from the directors as on March 31, 2015, taken on record by the Board of Directors, none of the directors is disqualified as on March 31,2015, from being appointed as a director in terms of Section 164 (2) of the Act; and

9 With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us;

i. The Company has disclosed the impact of pending litigations on its financial position in its financial statements as referred to in Note 23 to the financial statements;

ii. The Company has made provision, as required under the applicable law or accounting standards, for material foreseeable losses, if any, and as required on long-term contracts including derivative contracts; and

iii. The point regarding delay in transferring any amounts to the Investor Education and Protection Fund is not applicable to the Company.

For T.N. Unni & Co Chartered Accountants

Firm Regn. No. 004890C

Place : lndore Date : 291h May 201 5

I;., ,- ., 2) T.N. ~ n n i .; .- - d *;.. 4 &*qYC

(Partner) K M.M.No. 014520




Annexure to the Independent Auditor's Report

The Annexure referred to in our independent Auditor's Report to the members of the Company on the Statements for the year ended March 31, 201 5, we report that:

(i) The Company does not have any fixed assets.

(ii) The Company has no trading activities during the year.

(i i i) A) The Company has granted loans tol(one) party corporate covered in the register

maintained under section 189 of the Companies Act, 201 3 ("the Actn).The Maximum amount involved during the year and at the year ended balance of such loan aggregated to Rs. 57.45 lacs and Rs. 57.45 lacs respectively.

B) In view of reciprocal arrangement for the mutual benefit of the group companies, the rate of interest and other terms and conditions of unsecured loan granted by the company, are prima facie not prejudicial to the interest of the Company.

C) Payment of the principal amount and interest are also regular during the year.

(iv) In our opinion and according to the information and explanation given to us, there is an adequate internal control system commensurate with the size of the Company and the nature of its business with regard to purchase of fixed assets and sale of services. The activities of the Company do not involve purchase of inventory and the sale of goods. We have not observed any major weakness in the internal control system during the course of the audit.

(v) The Company has not accepted any deposits from the public.

(vi) Maintenance and cost audit of cost records has not been prescribed for the products Of the company by the Central Government, under Section 148 (1) of the Companies Act, 2013

(vii) According to the information and explanation given to us and on the basis of our examination of the records of the Company, amounts deductedlaccrued in the books of account in respect of undisputed statutory dues including provident fund, income tax, sales tax, wealth tax, service tax, duty of customs, value added tax, cess and other material statutory dues have been regularly deposited during the year by the Company with the appropriate authorities.




According to the information and explanation given to us, no undisputed amounts payable in respect of provident fund, income tax, sales tax, wealth tax, service tax, duty of customs, value added tax, cess and other material statutory dues were in arrears as at 31 March 2015 for a period of more than six months from the date of they became payable.

(viii) The Company has neither has accumulated losses as at March 31, 2015 nor has incurred any cash losses during the financial year ended on that date or in the immediately preceding financial year.

(ix) On the basis of information and explanation given by the Management in our opinion that the Company has not availed any borrowing from banks.

(x) The Company has not given any Guarantee for loans taken by others from banks or financial institutions.

(xi) The Company has not availed any fresh term loan during the current financial year 2014-1 5.

(xii) According to the information and explanations given to us and the examination of the records we have neither come across any instance of fraud on or by the Company, noticed or reported during the year, nor have we been informed of any such case by the Management.

For T.N. Unni & Co Chartered Accountants

Firm Regn. No. 0048906

Place : lndore Date : 2gth May 201 5

T.N. Unni (Partner)

.No. 014520

Parenteral Biotech Limited Mumbai

t- - A t ; /

BALANCE SHEET AS AT 31ST MARCH, 2015

Particulars

I. EQUITY AND LIABILITIES

11) Shareholder's Funds (a) Share Capital (b) Reserves and Surplus

12) Non-Current Liabilities Long-Term Borrowings

13) Current Liabilities (a) Trade Payables (b) Other Current Liabilities

Total Equity & Liabilities

II .ASSETS

jl) Non-Current Assets (i) Tangible assets (ii) lntangible assets (ii) Capital work in progress (iv) Intangible assets under development Total Fixed Assets

(b) Non-current investments (c) Deferred tax assets (net) (a) Long term loans and advances (b) Other non-current assets

[Z) Current Assets (a) Cash and cash equivalents (b) Other current assets

Total Assets

Significant Accounting Policies & Notes on Financial Statement

Referred to in our Report of even date FOR T. N. UNNl & CO. FOR PARENTERAL BIOTECH LIMITED CHARTERED ACCOUNTANTS Firm Regn No. 004890C--

1;-

/", ',.': J

.- , ,:) ,Ji'P -Ycrr(- T. N. Unni r L- 4 .K. ~ u p t a G. D. a*i7 Garg < (Partner) \ .

. .y,' Director Director

Membership No. : 014~0>~~" DIN 00039145 DIN 00520067 lndore

Dated : 29th May 2015

Note No.

2

3

4

5 6

7

7

8 9

10 11

1 to 16

As at 31st March

2015

2,500,000 3,380,850

9,963

7,684

5,898,497

5,800,677 28,888

66,846 2,086

5,898,497

(Amount in INR)

As at 31st March 2014

2,500,000 3,380,850

38,929,248

8,518

44,818,616

44,727,462

89,068 2,086

44,818,616

Parenteral Biotech Limited Cash Flow Statement for the year ended on 31st March 2015

lAmount In INRI

A - CASH FLOW FROM OPERATING ACTIVITIES : Net profitJloss before tax and extra-ordinary items

adjustment for : 1. Depreciation 2. InterestIDividend 3. Miscellaneous expenditure

Operating profit before working capital change

adjustment for : I I I 1. Trade and other receivable 2. Inventories 2. Trade and other Payable

Cash Generated from Operation

1. Interest Paid 2. Direct Taxes Paid

l ~ a s h Flow Before Extraordinary Items

Extra ordinary Items

I l e t cash from operating activities ..... A

B -CASH FLOW FROM INVESTING ACTIVITIES :

Misc. Exp. lssue of debit note for fixed assets Issue of debit note for misc expenses

I Net Cash used In Investing activlt ia .... B

I C - C4SW FLOW FROM FINANCING ACTIVITIES : I I I Receipt From Unsecured Loans Proceeds from long term borrowings Proceeds from share capital Received from Finance Liabilities Repayment of Long Term borrowings

Net Cash f rom Financing Activities .... C

Net inereaseldecrease i n Cash &Cash equivalents (A+B+C)

lopening cash and Cash equivalents Balances

FOR T. N. UNNl & CO.

CHARTERED ACCOUNTANTS

Closing Cash and Cash equivalents Balances

FOR PARENTERAL BIOTECH LIMITED I

I

I 66,846 1 89,068

Firm Regn No. 004890C

89,068

I I- , r .."mi IPrkPrk ',:,; \..:,,, - (Partner) . - . c Membership No. : 014520

111,299

V.K. Gupta 6. D. Garg

Director Director

DIN00039145 DIN00520067 lndore


Notes Forming Integral Part of the Balance Sheet as a t 31St March, 2015

Note : 1 Significant Accounting Policies

Basis of Prepartation of Financial Statement The Financial Statements are prepared at historical costs convention on the basis of going concern in accordance with the generally accepted accounting principles in India and the provision of the Companies Act, 2013. Figures for the previous year have been re-grouped and rearranged wherever considered necessary. Figures in bracket are represent corresponding previous year unless otherwise stated.

Fixed Assets Fixed Assets are stated at historical cost net of recoverable taxes, less accumulated depreciation and impairment loss, if any. All cost, including finance.cost, till assets putto use are capitalised.

Depreciation and arnortisation Deprication is not charged on Work In Process

Recognition of Revenue and Expenditure No account for Profit and Loss is taken until the unit commences business and until that date, all expenses are capitalized.

Note : 2 Share Capital

Sr. No

1

a

2 a .

As at 31st March

2014

5,000,000

5,000,000

2,500,000

2,500,000

Particulars

Authorized Share Capital 5,00,000 (5,00,000) Equity Shares of Rs. 10 each

Issued, Subscribed & Paid Up Capital (fullv paid) 2,50,000 (2,50,000) Equity Shares of Rs. 10 each

Total

a

b

c

d


5,000,000

5,000,000

2,500,000

2,500,000

Reconciliation of Shares outstanding at the beginning and atthe end of the year 31.03.2014

Nos.

250,000

250,000

E~u i tv Shares

A t the Beginning of the year Issued during the year Outstanding at the end of the year

31.03.2015 Nos.

250,000

250,000

Terms / Rights Attached to Shares Equity Shares The Company has only one class of equlty shares having a par value of Rs. lo/-. Each holder of equity share IS entitled to one vote per shares. The Company declares and pays dividends in Indian rupees.The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting.

In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the company, after distribution of all preferential amounts. The distribution will be In proportion to the number of equity shares held by the shareholders.

Shares held by Holding Company (51% subsidiary)

Equity Shares

Name of Shareholders holding more than 5% shares of the Company

- Equity Shares - Parenteral Drugs (India) Limited - Equity Shares - Mahaganpati Investments Private Limited

31.03.2015 Nos.

127,500

31.03.2015 Nos.

127,500 122,500

31.03.2014 Nos.

127,500

31.03.2014 NOS.

127,500 122,500


Notes Forming Integral Port of the Bolonce Sheet as at 31St March, 2015 Note : 3 Reserve & Surplus

I I Loans 81 Advances From Related Parties I 9,963 1 38,929,248 1

Note : 4 Long Term Borrowings


2,000,000 1,380,850

3,380,850

Sr. NO


2,000,000 1,380,850

3,380,850

Sr, No

1 2

Note :

Particulars

General Reseve Surplus (Profit & Loss Account)

Total

Note : 6 Other Current Liabilities

Long Term Loans and Advances (Unsecured, Considered Good) 1 Security Deposit I I

As a t 31st March

2014 Particulars

Unsecured

p~

5 Trade Payable

Note : 8 Long Term Loons and Advances

As a t 31st March

2015


Sr. NO

Sr. No As at 31st March

2014

As at 31st March

2014

8,518 8,518

Particulars

Micro, Small & Medium Enterpirses Others Total

2 3

Ye-


7,684 7,684

Particulars

TDS Payable

Total

Particulars

Loans & Advances to related parties Other Trade Advances (Recoverable in cash or in kind or value to be received)

Disclosure as per Micro, Small and Medium Enterprises Development Act, 2006 On the basis of information available, there are no outstanding dues in excess of Us. 1.00 lac each payable to SSI units for more than 30 days in so far as they could be identified as per Micro, Small and Medium Enterprises Development Act, 2006.




Particulars

Principal amount & interest due and remainlng unpaid lnterest paid Payment made beyond the appointed day during the year Interest due and payable for the period of delay lnterest accrued and remaining unpaid Amount of further interest remainingdue and payable in succeeding year:


Parenteral Biotech Limited Murnbai

Notes Forming Integral Part of the Balance Sheet as at 3 1 9 March, 2015

Note : 10 Cash & cash equivalents

Note : 9 Other Non Current Assets As at 31st March

2014

S r . NO

1 2


28,888

Sr. No

1

2

Note : 11 Other current assets

Particulars

Preliminary Expenses (To the extent not written off or adjusted) Pre-operative Expenses (To the extent not written off or adjusted)

Particulars

Balance with Bank Cash on Hand


2,086

2,086


64,947 1,899


2,086

2,086

Sr. No


84,089 4,979

Particulars

Advance Income Tax & TDS

Total


Notes Fomlng Integral Part of the Balance Sheet as at 31st March, 2015

Note 13

Note 15 :Segmental Reporting

The Company is principally engaged in the business of pharmaceutical. Accordingly there are no segments as per

Accounting Standard 17 "Segmental Reporting" issued by the Institute of Chartered Accountants of India.

In the opinion of the Board of Directors of the Company the Current Assets, Loan &Advances have

a value on realisation in the ordinary course of business at least equal to the amount at which they are stated

and provision for all known liabilities are adequate and not in excess of the amount reasonably necessary.

Note 14 :Auditors Remuneration

Particulars

Audit Fees

Total

Referred to In our Report of even date

FOR T. N. UNNI & CO. FOR PARENTERAL BIOTECH LIMITED

V.K. Gupta / G. D. ~ a r h

(Partner) , Director Director

DIN 00039145 DIN 00520067

lndore

Dated : 29th May 2015.

Note 16 :


3,WO

3,000


3,000

3,000

Related Party Disclosures

(a) Holding Company Parenterai Drugs (India) Limited

(b) Other related party relationship where transactions have taken place during the year Fellow Subsidiary

1 lnfutec Healthcare Limited 2 Parenteral Surgicals Limited

Enterorises over which Kev Mananerial Personnel exercise slgnlflcant influence Mahangapati investments Private Limited

(c) summary of Related Party Transactions

a) 1

2

b)

Particulars

Transaction Unsecured loan recd

Expenses Debit Note

Outstanding Balances as on 31st March 2015

Holding Company

Enterprises controlled by key

management/ relatives

7,500 (15,098,775)

(44,672,461)

5,745,675 (5,753,176)

Documents

PARENTERAL BIOTECH LIMITED I · 2016-04-25 · PARENTERAL BIOTECH LIMITED Regd. Office.: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andlieri (West), Mumbai- 400 053